Samuels Theodore R. II 4

What Happened

• Theodore R. Samuels II, a director of Bristol Myers Squibb (BMY), received an award of 889.448 Deferred Share Units on 2026-06-30. The units are reported as a derivative grant valued at $57.62 per share, totaling approximately $51,250.
• This is an award/compensation grant (code A), not an open‑market purchase or sale. Such grants are common for non-employee director compensation and are not a direct buy/sell signal.

Key Details

• Transaction date: 2026-06-30; reported on SEC Form 4 filed 2026-07-02.
• Instrument: 889.448 Deferred Share Units (derivative), reported price basis $57.62; aggregate value ~$51,250.
• Shares owned after transaction: not specified in the filing.
• Footnote F1: Each Deferred Share Unit converts into one share of common stock upon settlement; they become settleable when the director leaves the board or at a future date the reporting person specified.
• Footnote F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• Transaction type: Award/grant (code A) — no immediate cash transaction or sale reported.

Context

• Deferred Share Units are a form of compensation that convert to actual shares at settlement (often upon departure or a preset date); they are reported as derivative awards rather than immediate purchases. For retail investors, awards to directors are routine compensation and do not, by themselves, indicate insider buying or selling intent.